BR112012025590A2 - análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 - Google Patents
análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119Info
- Publication number
- BR112012025590A2 BR112012025590A2 BR112012025590A BR112012025590A BR112012025590A2 BR 112012025590 A2 BR112012025590 A2 BR 112012025590A2 BR 112012025590 A BR112012025590 A BR 112012025590A BR 112012025590 A BR112012025590 A BR 112012025590A BR 112012025590 A2 BR112012025590 A2 BR 112012025590A2
- Authority
- BR
- Brazil
- Prior art keywords
- gpr119
- coupled receptor
- pyrimidinylpiperidinyloxypyridinone
- analogues
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. a presente invenção refere-se a compostos de fórmula estrutural ou um enantiômero, um diastereômero, ou um sal farmaceuticamente aceitável dos mesmos, em que, n~ 1~, r^ 1^, r^ 2^, r^ 3^ e r^ 4^ são definidos aqui, são fornecidos os quais são moduladores de receptor acoplado à proteína g gpr119. moduladores de receptor acoplado à proteína g gpr119 são úteis no tratamento, prevenção, ou retardo da progressão de doenças que requerem terapia moduladora de receptor acoplado à proteína g gpr119. desse modo, a descrição também diz respeito a composições compreendendo estes novos compostos e métodos de tratar doenças ou condições relacionadas à atividade do receptor acoplado à proteína g gpr119 usando-se quaisquer destes novos compostos ou uma composição compreendendo quaisquer de tais novos compostos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32194610P | 2010-04-08 | 2010-04-08 | |
PCT/US2011/031320 WO2011127106A1 (en) | 2010-04-08 | 2011-04-06 | Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012025590A2 true BR112012025590A2 (pt) | 2016-06-21 |
Family
ID=44021850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012025590A BR112012025590A2 (pt) | 2010-04-08 | 2011-04-06 | análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8415367B2 (pt) |
EP (1) | EP2556069B1 (pt) |
JP (1) | JP2013523822A (pt) |
CN (1) | CN102933576A (pt) |
AR (1) | AR081819A1 (pt) |
BR (1) | BR112012025590A2 (pt) |
CA (1) | CA2795732A1 (pt) |
EA (1) | EA201270755A1 (pt) |
IL (1) | IL222220A0 (pt) |
MX (1) | MX2012011460A (pt) |
SG (1) | SG184168A1 (pt) |
TW (1) | TW201136917A (pt) |
UY (1) | UY33323A (pt) |
WO (1) | WO2011127106A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
EP2691083B1 (en) * | 2011-03-29 | 2017-08-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition of sitagliptin |
JP6463631B2 (ja) | 2011-06-09 | 2019-02-06 | ライゼン・ファーマシューティカルズ・エスアー | Gpr−119のモジュレータとしての新規化合物 |
US9174965B2 (en) | 2012-05-16 | 2015-11-03 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators |
CN104780915A (zh) | 2012-07-11 | 2015-07-15 | 埃尔舍利克斯治疗公司 | 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物 |
WO2014052619A1 (en) * | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CN104418769A (zh) * | 2013-09-03 | 2015-03-18 | 苏州安尼康药物研发有限公司 | 一种化合物及其制备方法 |
CN105968055B (zh) * | 2016-07-26 | 2018-08-28 | 中国科学院长春应用化学研究所 | 一种芳基嘧啶及其衍生物的制备方法 |
UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826643A (en) | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
DE69940063D1 (de) | 1998-07-06 | 2009-01-22 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
AU3127900A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
CA2413241A1 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
JP3438186B2 (ja) | 2000-12-01 | 2003-08-18 | 山之内製薬株式会社 | 糖尿病治療剤スクリーニング方法 |
JP5082033B2 (ja) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | Lxrのモジュレーター |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
KR20110010824A (ko) | 2003-01-14 | 2011-02-07 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료 |
PL378295A1 (pl) | 2003-02-24 | 2006-03-20 | Arena Pharmaceuticals, Inc. | Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
JP4920410B2 (ja) | 2003-07-14 | 2012-04-18 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療 |
US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
JP2007529463A (ja) | 2004-03-17 | 2007-10-25 | 7ティーエム ファーマ エイ/エス | 治療的介入のためのy4選択性レセプターアゴニスト |
PL1756096T3 (pl) | 2004-05-03 | 2010-01-29 | Hoffmann La Roche | Pochodne indolilowe jako modulatory wątrobowych receptorów X |
PE20060530A1 (es) | 2004-06-04 | 2006-06-28 | Arena Pharm Inc | Aril y heteroaril derivados sustituidos como moduladores del metabolismo de la glucosa |
JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Gタンパク質結合受容体作動薬 |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
EP1893246A4 (en) | 2005-06-23 | 2009-05-06 | Univ Emory | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGUE FOR TUMOR IMAGING |
US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
CN101668759A (zh) | 2007-05-04 | 2010-03-10 | 百时美施贵宝公司 | [6,5]-双环gpr119g蛋白-偶合受体激动剂 |
ES2388967T3 (es) | 2007-05-04 | 2012-10-22 | Bristol-Myers Squibb Company | Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G |
NZ582664A (en) | 2007-07-17 | 2012-03-30 | Bristol Myers Squibb Co | Pyridone gpr119 g protein-coupled receptor agonists |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
-
2011
- 2011-04-06 MX MX2012011460A patent/MX2012011460A/es active IP Right Grant
- 2011-04-06 WO PCT/US2011/031320 patent/WO2011127106A1/en active Application Filing
- 2011-04-06 EP EP11715129.0A patent/EP2556069B1/en not_active Not-in-force
- 2011-04-06 BR BR112012025590A patent/BR112012025590A2/pt not_active Application Discontinuation
- 2011-04-06 US US13/080,758 patent/US8415367B2/en active Active
- 2011-04-06 CN CN2011800285354A patent/CN102933576A/zh active Pending
- 2011-04-06 CA CA2795732A patent/CA2795732A1/en not_active Abandoned
- 2011-04-06 JP JP2013503864A patent/JP2013523822A/ja not_active Withdrawn
- 2011-04-06 SG SG2012069746A patent/SG184168A1/en unknown
- 2011-04-06 EA EA201270755A patent/EA201270755A1/ru unknown
- 2011-04-08 TW TW100112288A patent/TW201136917A/zh unknown
- 2011-04-08 AR ARP110101204A patent/AR081819A1/es not_active Application Discontinuation
- 2011-04-08 UY UY0001033323A patent/UY33323A/es unknown
-
2012
- 2012-09-27 IL IL222220A patent/IL222220A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2556069A1 (en) | 2013-02-13 |
IL222220A0 (en) | 2012-12-31 |
US20110251221A1 (en) | 2011-10-13 |
AR081819A1 (es) | 2012-10-24 |
SG184168A1 (en) | 2012-10-30 |
EA201270755A1 (ru) | 2013-03-29 |
TW201136917A (en) | 2011-11-01 |
US8415367B2 (en) | 2013-04-09 |
WO2011127106A1 (en) | 2011-10-13 |
UY33323A (es) | 2011-10-31 |
MX2012011460A (es) | 2012-11-23 |
EP2556069B1 (en) | 2015-04-01 |
CA2795732A1 (en) | 2011-10-13 |
JP2013523822A (ja) | 2013-06-17 |
CN102933576A (zh) | 2013-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012025590A2 (pt) | análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 | |
BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
BR112012007979A2 (pt) | moduladores de gpr40 de pirrolidina | |
BR112015011031A2 (pt) | moduladores de grp40 de di-hidropirazol | |
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
EA201200406A1 (ru) | Соединения и композиции, которые являются модуляторами активности tlr | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CA2797033C (en) | Highly active polypeptides and methods of making and using the same | |
BR112012011072A2 (pt) | inibidores de n1-pirazolospirocetona acetil-coa carboxilase | |
BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BR112016009630A8 (pt) | receptores de farnesoide x, seus usos, composição farmacêutica, e combinação | |
BR112015007182A2 (pt) | inibidores de gdf-8 | |
EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
BRPI0518222A (pt) | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos | |
BR112013003847A8 (pt) | métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados | |
BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
JO3297B1 (ar) | تركيبات و طرق لتعديل fxr | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
BR112012030820A2 (pt) | "derivados de aminopirimidina como moduladores de lrrk2" | |
BR112015010649A2 (pt) | moduladores de gpr40 à base de pirrolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |